lapatinib has been researched along with Hormone-Dependent Neoplasms in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guarneri, V | 1 |
| Abrahámová, J; Bacanu, F; Brincat, S; Brize, A; Cesas, A; Cufer, T; Dank, M; Duchnowska, R; Eniu, A; Jassem, J; Kahán, Z; Matos, E; Padrik, P; Plāte, S; Pokker, H; Purkalne, G; Steger, GG; Timcheva, C; Tzekova, V; Vyzula, R; Zielinski, CC | 1 |
| Anderson, L; Britten, CD; Christensen, JG; Cohen, DJ; Conklin, D; Desai, AJ; Finn, RS; Ginther, C; Kalous, O; O'Brien, NA; Slamon, DJ; Taylor, I | 1 |
| Bozovic-Spasojevic, I; de Azambuja, E; Zardavas, D | 1 |
| Conaway, M; Gioeli, D; Theodorescu, D; Weber, MJ; Wu, Z | 1 |
2 review(s) available for lapatinib and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Lapatinib plus letrozole for postmenopausal patients with advanced HER2(+)/HR(+) breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorouracil; Humans; Lapatinib; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quinazolines; Receptor, ErbB-2; Trastuzumab; Triazoles | 2009 |
Dual human epidermal growth factor receptor 2 blockade: another step forward in treating patients with human epidermal growth factor receptor 2-positive breast cancer.
Topics: Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Lapatinib; Molecular Targeted Therapy; Neoplasms, Hormone-Dependent; Quinazolines; Quinolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2012 |
4 other study(ies) available for lapatinib and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Breast cancer drug approved for new indication.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Administration Schedule; Drug Approval; Drug Therapy, Combination; Female; Humans; Lapatinib; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quinazolines; Triazoles; United States; United States Food and Drug Administration; Women's Health | 2010 |
Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel.
Topics: Algorithms; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Delivery Systems; Drug Therapy, Combination; ErbB Receptors; Europe; Evidence-Based Medicine; Female; Humans; Lapatinib; Neoplasm Staging; Neoplasms, Hormone-Dependent; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2010 |
Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Amplification; Humans; Inhibitory Concentration 50; Lapatinib; Neoplasms, Hormone-Dependent; Phosphorylation; Protein Processing, Post-Translational; Quinazolines; Quinazolinones; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Trastuzumab | 2012 |
Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors.
Topics: Benzamides; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Chromones; ErbB Receptors; Gefitinib; Humans; Lapatinib; Male; Mitogen-Activated Protein Kinases; Morpholines; Neoplasms, Hormone-Dependent; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Prostatic Neoplasms; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines | 2008 |